KLRA
Kailera Therapeutics, Inc.Company Information
- Company Name
- Kailera Therapeutics, Inc.
- CIK
- CIK0002096997
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- KLRA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- KLRA
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-04-20
- Last sale
- —
- Shares purchased (TTM)
- 20,421,876
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 112,793,104
- Shares outstanding
- 102,226,608
- Ownership
- 110.34%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- -12.70%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||
| Cash And Cash Equivalents At Carrying Value | 130 | 112 | ||||||
| Marketable Securities Current | 786 | 407 | ||||||
| Prepaid Expense And Other Assets Current | 12 | 11 | ||||||
| Assets Current | 929 | 530 | ||||||
| Property Plant And Equipment Net | 2 | 2 | ||||||
| Restricted Cash Noncurrent | 1 | 1 | ||||||
| Marketable Securities Noncurrent | 255 | 63 | ||||||
| Operating Lease Right Of Use Asset | 10 | 10 | ||||||
| Other Assets Noncurrent | 0 | 6 | ||||||
| Assets | 1,211 | 625 | ||||||
Liabilities Current | ||||||||
| Accounts Payable Current | 19 | 7 | ||||||
| Accrued Liabilities Current | 63 | 47 | ||||||
| Operating Lease Liability Current | 1 | 1 | ||||||
| Liabilities Current | 84 | 55 | ||||||
| Operating Lease Liability Noncurrent | 9 | 9 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | ||||||
| Liabilities | 93 | 64 | ||||||
Temporary Equity | ||||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | 992 | ||||||
Stockholders Equity | ||||||||
| Preferred Stock Value | 0 | - | ||||||
| Common Stock Value | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 1,679 | 16 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -2 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -559 | -448 | ||||||
| Stockholders Equity | 1,118 | -432 | ||||||
| Liabilities And Stockholders Equity | 1,211 | 625 | ||||||
| Temporary Equity Par Or Stated Value Per Share | 0.00 | 0.00 | ||||||
| Temporary Equity Shares Authorized | 10 | 79 | ||||||
| Temporary Equity Shares Issued | 0 | 79 | ||||||
| Temporary Equity Shares Outstanding | 0 | 79 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | - | ||||||
| Preferred Stock Shares Authorized | 10 | - | ||||||
| Preferred Stock Shares Issued | 0 | - | ||||||
| Preferred Stock Shares Outstanding | 0 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 800 | 105 | ||||||
| Common Stock Shares Issued | 130 | 0 | ||||||
| Shares Outstanding | 130 | 0 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialKailera Therapeutics, Inc. (KLRA) — SEC Financial Statements & Analysis
Kailera Therapeutics, Inc. (KLRA) is a pharmaceutical preparations company, incorporated in DE. Kailera Therapeutics, Inc. trades on Nasdaq as: KLRA. Kailera Therapeutics, Inc. (KLRA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Kailera Therapeutics, Inc. carries a market cap of $2.25B, a P/B ratio of 2.01x, and an enterprise value of $2.12B. On the balance sheet, it maintains a current ratio of 11.11x, a quick ratio of 10.96x, working capital of $845.52M, a debt-to-equity ratio of 0.08x, a debt ratio of 0.08, and net debt of $-131.06M. Figures sourced from SEC EDGAR.
- Market Cap
- $2.25B
- P/B TTM
- 2.01x
- Debt To Equity
- 0.08x
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Kailera Therapeutics, Inc. in?
Kailera Therapeutics, Inc. (KLRA) operates in the Pharmaceutical Preparations industry.
What exchange does KLRA trade on?
Kailera Therapeutics, Inc. (KLRA) trades on the Nasdaq.
Where is Kailera Therapeutics, Inc. incorporated?
Kailera Therapeutics, Inc. is incorporated in DE.
When was Kailera Therapeutics, Inc. (KLRA)'s most recent SEC filing?
Kailera Therapeutics, Inc. (KLRA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is KLRA's market cap?
Kailera Therapeutics, Inc. (KLRA) has a market capitalization of $2.25B as of 2026-06-30.